InnoCare Pharma Limited (HKG:9969)

Market Cap	24.43B +21.1%
Revenue (ttm)	2.87B +105.9%
Net Income	830.13M
EPS	0.49
Shares Out	1.70B
PE Ratio	23.81
Forward PE	88.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,077,000
Open	11.75
Previous Close	11.75
Day's Range	11.46 - 11.90
52-Week Range	10.06 - 20.62
Beta	0.35
Analysts	Strong Buy
Price Target	19.88 (+72.72%)
Earnings Date	Aug 19, 2026

About InnoCare Pharma

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 1,176
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9969

Financial Performance

Financial numbers in CNY